MétaCan
Menu
Back to cohort
Record W4312114026 · doi:10.1038/s41408-022-00760-z

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

2022· review· en· W4312114026 on OpenAlexafffund
Farhad Ravandi, Robert J. Kreitman, Enrico Tiacci, Leslie A. Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema A. Bhat, James S. Blachly, Alessandro Broccoli, Timothy G. Call, Dai Chihara, Claire Dearden, Judit Demeter, Sasha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E. Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B. Johnston, Jeffrey L. Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A. Parikh, Jae H. Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A. Rogers, Alan Saven, John F. Seymour, Tamar Tadmor, Martin S. Tallman, Constantine S. Tam, Philip A. Thompson, Xavier Troussard, Clive S. Zent, Thorsten Zenz, Pier Luigi Zinzani, Bernhard Wörmann, R. Kanti, Michael R. Grever

Bibliographic record

VenueBlood Cancer Journal · 2022
Typereview
Languageen
FieldMedicine
TopicChronic Lymphocytic Leukemia Research
Canadian institutionsKingston Health Sciences CentreUniversity of ManitobaCancerCare Manitoba
FundersCilagPharmacyclicsKite PharmaCanadian Institutes of Health ResearchIpsenMorphoSysAssociazione Italiana per la Ricerca sul CancroAptitude HealthCancer Research UKAscentage PharmaBeiGeneCelltrionHairy Cell Leukemia FoundationAdaptive BiotechnologiesAstex PharmaceuticalsTG TherapeuticsGenentechBlood Cancer UKAmicus TherapeuticsIncytePfizerBiogenUniversity of RochesterCancerCare Manitoba FoundationMEI PharmaDaiichi-SankyoMacroGenicsSunesisUniversity of PittsburghNational Cancer InstituteServierGilead SciencesTeva Pharmaceutical IndustriesLeukemia and Lymphoma SocietySanofiIpsen BiopharmaceuticalsCelgeneBristol-Myers SquibbAstraZenecaAmgenNational Institutes of HealthLeukemia and Lymphoma Society of CanadaGlaxoSmithKline
KeywordsMinimal residual diseaseOncologyMedicineBone marrowInternal medicineLeukemiaFlow cytometryHematologyHairy cell leukemiaDiseaseCancer researchImmunology

Abstract

fetched live from OpenAlex

A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell leukemia (HCL). However, due to the indolent nature of the disease as well as reports suggesting long-term survival in patients treated with a single course of a nucleoside analog albeit without evidence of cure, the merits of detection of MRD and attempts to eradicate it have been debated. Studies utilizing novel strategies in the relapse setting have demonstrated the utility of achieving CR with undetectable MRD (uMRD) in prolonging the duration of remission. Several assays including immunohistochemical analysis of bone marrow specimens, multi-parameter flow cytometry and molecular assays to detect the mutant BRAF V600E gene or the consensus primer for the immunoglobulin heavy chain gene (IGH) rearrangement have been utilized with few comparative studies. Here we provide a consensus report on the available data, the potential merits of MRD assessment in the front-line and relapse settings and recommendations on future role of MRD assessment in HCL.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.007
metaresearch head score (Gemma)0.012
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.008
Threshold uncertainty score0.037

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0070.012
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0030.002
Science and technology studies0.0010.001
Scholarly communication0.0030.003
Open science0.0030.002
Research integrity0.0070.006
Insufficient payload (model declined to judge)0.0080.006

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.100
GPT teacher head0.403
Teacher spread0.303 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations23
Published2022
Admission routes2
Has abstractyes

Explore more

Same venueBlood Cancer JournalSame topicChronic Lymphocytic Leukemia ResearchFrench-language works237,207